Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunity Duration and bOPV Booster Effectiveness Study
NCT03821441Phase 3Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jan 2018
- Primary completion
- May 2020
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bivalent oral poliovirus vaccine in poliomyelitis (3 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoints: Positive rate of anti-poliovirus antibodies at aged 24 months, Positive rate of anti-poliovirus antibodies at aged 36 months and 1 more. Status: unknown.
02
Drugs
bivalent oral poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT03821441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821441.